In the ex vivo analysis of the VCaP tumor samples for effects on the AR signaling pathway, we found a significant reduction of FKBP5 and TMPRSS2 expression after enzalutamide treatment, but no significant changes were seen in the BAY-155 treated study arm (Figure 6C). This evidence concerns the gene TMPRSS2 and neoplasm.